Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
September 01 2010 - 3:00AM
Business Wire
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc.
(NASDAQ: ISIS) announced that data from the phase 3 study of
mipomersen in patients with heterozygous familial
hypercholesterolemia (heFH) were presented today at the European
Society of Cardiology’s Congress 2010 in Stockholm, Sweden. The
study met its primary endpoint with a 28 percent reduction in
LDL-cholesterol, compared with an increase of 5 percent for placebo
(p
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Apr 2024 to May 2024
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From May 2023 to May 2024